Back

Real-world impact of intermittent levosimendan on survival, hospitalizations, and healthcare costs in advanced heart failure

31 August 2025 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Trends and challenges in heart failure management Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Joao Fernandes Pedro

Santa Maria Hospital - CHULN, Lisbon (Portugal)

7 More presentations in this session

Presentation thumbnail
Prediction model of rehospitalization in heart failure with preserved and mildly-reduced ejection fraction: the AD2NER risk score
Doctor F. Stoiculescu (Craiova, RO)
Abstract Slides Video
Presentation thumbnail
Prevalence, prognosis, and factors associated with heart failure with improved ejection fraction: single centre experience
Doctor M. Vidak (Zagreb, HR)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of cardio-renal-anemia syndrome in heart failure - a report from the JROADHF database.
Doctor E. Noda (Fukuoka, JP)
Abstract Slides Video
Presentation thumbnail
Heart failure hospitalization and mapping of post-discharge care: insights from a slovakian cohort study
Mr M. Selvek (Bratislava, SK)
Abstract Slides Video
Presentation thumbnail
Delay in assistance effects in cardiology consultation following primary care physician referral in heart failure patients
Professor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Trends and challenges in heart failure management

The Event

Event poster

ESC Congress 2025

31 August 2025 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Intermittent levosimendan therapy and survival outcomes in advanced heart failure: insights from a real-world single-centre study
thumbnail
Congress Presentation
Reducing the burden of advanced heart failure: a clinical and economical analysis of an intermittent Levosimendan programme
thumbnail
Congress Presentation
Intermittent levosimendan in advanced palliative heart failure improves quality of life and reduces heart failure decompensations: a single center-experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources